Multiple myeloma is a plasma cell malignancy of monoclonal origin predominantly located in the bone marrow (BM) . It is the most common form of lymphoid malignancy, occurring primarily in the elderly, and the incidence is increasing (Mellstedt et al., 1984; Barlogie et al., 1989 ). Myeloma cells are categorised by the degree of differentiation and by growth pattern in BM, and both of these parameters have been shown to correlate with prognosis (Bartl et al., 1982; Croese, 1987a) . Standard therapy for multiple myeloma consists of melphalan chemotherapy with or without prednisolone and/ or hemi-body irradiation but even with treatment, median survival time is only 30-40 months (McElwain & Rowels, 1983; Alexanian & Dreicer, 1984; Kyle et al., 1986; Barlogie et al., 1987; Hjorth et al., 1990; Barlogie, 1991) .
In 1988 Radl et al. described the 5T series of transplantable murine multiple myelomas which are remarkably similar to the human disease. Both the murine and human myeloma demonstrate progressive monoclonal proliferation, paraproteinemia (most frequently IgG) which generally increases with tumour progression, and atypical ('myeloma') plasma cells (Radl et al., 1988) . The murine myelomas arose spontaneously in aged C57BL/KaLwRij mice with a frequency of approximately 0.5% and have been maintained in vivo by the intravenous (i.v.) transfer of BM cells into syngeneic recipients (Radl et al., 1988) . As an animal model representative of human multiple myeloma, the 5T series of transplantable murine myelomas has allowed detailed studies on the basic biology and histopathology of this malignancy (Radl et al., 1985; Croese, 1987a; Croese et al., 1987b; Radl et al., 1988) . Initial studies of immunoregulation of multiple myeloma and response to immunological treatment using anti-idiotypic monoclonal antibodies have also been performed in the murine model (Croese et al., 1991a (Croese et al., , 1991b Establishment of 5T33 in vitro as a cultured cell line The tibiae and femorae of tumour-bearing animals were collected aseptically and single cell suspensions were prepared as previously described (Croese, 1987a; Croese et al., 1987b For cytological examination, cytospin samples (2 drops, 106 cells ml-') were prepared using a Shannon II cytospin centrifuge (750 g, 5 min, Department of Histopathology, Fremantle Hospital). The slides were immediately fixed in ethanol and stored at 4°C until used. The cell preparations were stained with May-Grunwald and examined by light microscopy.
Determination of 5T33 growth rate in culture To determine the growth rate of 5T33 myeloma cells in culture, 2.5 x 105 cells were seeded into large tissue culture flasks in 1O ml of complete medium. Cells were harvested from duplicate flasks every day for 6 days. Growth rate was determined using the formula: Immunofluorescence Expression of both surface and cytoplasmic IgG2b paraprotein in cultured 5T33 myeloma cells was determined by standard techniques (Hudson & Hay, 1980 ) using biotinylated sheep anti-mouse IgG2b (SAMIgG2b, 1: 50 dilution, Alpha Scientific, Langwarrin, Australia) followed by streptavidin-fluorescein (1:50 dilution, Amersham Australia, North Ryde, Australia). The isotype specificity of the SAMIgG2b was determined by ouchterlony gel diffusion assay (Serotec). Immunoglobulin-negative thymocytes and B16M melanoma cells served as negative controls for this reagent and demonstrated <1% staining.
The number of fluorescing cells was determined using an Olympus BH-2 fluorescence microscope (200 x magnification). Two hundred cells were counted on four different preparations for both surface and cytoplasmic fluorescence. Cells were also assessed by flow cytometry (Coulter Epics Profile Analyzer; Department of Biomedical Sciences, Curtin University, Perth, Western Australia) to evaluate possible differences in surface IgG2b expression as determined by fluorescence intensity. Five thousand cells were counted in four different preparations. 150 Lg ml-l and 5.0 mg ml-' could be detected using this method. The paraprotein standard consisted of 5T33 IgG2b purified from ascites by ammonium sulfate precipitation and Protein A column chromatography (Hudson & Hay, 1980) , and quantified by spectrophotometry (Novaspec II, Pharmacia) at 595 nm using a Coomassie protein assay (Pierce, Rockford, IL, USA).
Kinetics and tissue distribution of ST33 myeloma cells following intrajugular injection C57BL/KaLwRij mice were injected with 5 x 105 cultured 5T33 myeloma cells and every week for 5 weeks, three animals were euthanased and tissues were aseptically collected to determine tumour cell distribution. Single cell suspensions of the spleen, liver, bone marrow, thymus and lymph nodes were prepared and examined for the presence of cytoplasmic IgG2b positive cells as described above. Cytospin samples were also evaluated cytologically for the presence of plasma cells. Tissues from one age-matched and sex-matched control animal were processed at each timepoint to establish baseline values for each tissue. Blood samples were collected as described above and differential counts were performed using a STK-S Coulter Counter (Department of Haematology, Fremantle Hospital) to determine the effect of tumour progression on blood cell profiles.
Statistical analysis Data were analysed using the non-paired Student's t-test.
Results
Morphology, growth rate and IgG2b paraprotein expression of cultured 5T33 myeloma cells The 5T33 myeloma cell line has been in continuous culture for over 10 months and has achieved over passage 34. In culture, 5T33 myeloma grows as single cells or in small clusters of loosely adherent cells on an adherent stromal cell layer (Figure la) . Cytologically, these cells appear as abnormal plasma cells of variable size with a large, highly-granular nucleus and abundant cytoplasm (Figure lb) . Maximum doubling time of the myeloma cells (passage 15 to passage 20) was 24.9 ± 4.1 h (n = 14). Greater than 90% of the cultured 5T33 cells expressed cytoplasmic IgG2b paraprotein (Figure lc & d) . A much smaller proportion of the cultured 5T33 cells expressed surface IgG2b paraprotein (20.2 ± 1.7%, n = 6). In general, the amount of IgG2b expressed on the cell surface as determined by fluorescence intensity was inversely proportional to cell size (data not shown). Tumorigenicity of cultured 5T33 myeloma cells Cultured 5T33 myeloma cells were found to be highly tumorigenic in C57BL/KaLwRij mice with as few as 500 cells inducing paralysis and death as early as 36 days post-tumour inoculation (Figure 2 ). Survival time was directly related to tumour cell number. All of the animals injected with over 104 cells developed paraprotein and paralysis resulting in death by day 50 post-tumour inoculation, whereas none of the animals injected with 100 cells showed any sign of disease by day 80 (Figure 2 The increased tumour cell population in the spleen and liver occurred in parallel with a significant increase in the size and weight of these two tissues (P<0.01; Figure 4) . The proportion of tumour cells in the various tissues continued to increase with time, particularly in the liver and bone marrow where, by week 5, over 70% of the isolated cells were positive for cytoplasmic IgG2b. Similar liver, spleen and bone marrow involvement was observed when bone marrow cells from end-stage 5T33-bearing mice were used as the inoculum (data not shown).
Cytological evaluation of plasma cells in the various tissues demonstrated a similar pattern of tumour cell kinetics and distribution (Table I) . Approximately 70% of the nucleated cells isolated from the blood of tumour-bearing animals at week 5 were positive for cytoplasmic IgG2b compared with 7.9 ± 4.3% in control animals (n = 9, data not shown). IgG2b
._> paraprotein was first detected in the blood between day 14 and day 21 post-tumour inoculation and increased significantly to a maximum of 30 mg ml' by day 28 ( Figure 5 ).
Alterations in normal blood cell profiles occurred in parallel with tumour progression. A significant elevation in platelet number was observed at day 7 post-tumour inoculation but by day 21, the cell populations of platelets, red blood cells and white blood cells were significantly reduced and remained low throughout the 5 week observation period (P<0.01; Figure 6 ). 
Discussion
The 5T33 murine myeloma model is one of several multiple myelomas which arose spontaneously in aged C57BL/ KaLwRij mice (Radl et al., 1988) . These tumours have been maintained by transplantation into syngeneic recipients and have been used for detailed studies on several aspects of the biology, histopathology and immunoregulation of myeloma (Radl et al., 1985 (Radl et al., , 1988 Croese, 1987a; Croese et al., 1987b; Croese et al., 1991a Croese et al., , 1991b . These murine myelomas are remarkably similar to human multiple myeloma, and many of the findings may have direct clinical application.
Although this experimental animal model has proven invaluable for the in vivo study of myeloma, investigations have been limited by the lack of an in vitro cell line counterpart for this series of transplantable tumours. In particular, initial assessments of growth factor production and requirements for myeloma development cannot be evaluated in vivo or in short term in vitro cultures. Similarly, efficacy of the extensive range of chemical and biological agents now available for cancer therapy cannot be adequately assessed in an in vivo model due to the time and number of animals required to evaluate responses. We have established the 5T33 myeloma as an in vitro cultured cell line and characterised it in vivo to facilitate such studies. Day Figure 4 Effect of 5T33 myeloma progression on liver and spleen weights. Mice were inoculated with 5T33 cultured myeloma cells as described in Figure 3 . At weekly intervals, the liver and spleen were collected from at least three animals and weighed. The data is presented as the mean weight in grams ( ± s.d.) of the spleen and liver for 3-6 mice for each time point. Early studies in our laboratory comparing the cultured 5T33 myeloma cells to those isolated from in vivo passaged tumours found the cells to be indistinguishable with respect to cytology and IgG2b paraprotein expression, and both parameters were consistent with the original description of the spontaneous tumour (Radl et al., 1988) . The morphological heterogeneity and variability in surface paraprotein expression which we observed in cultured 5T33 myeloma cells have also been described for the transplantable 5T2 multiple myeloma model where such heterogeneity was found to reflect different stages of differentiation (Croese, 1987a; Croese et al., 1987b Tumorigenic potential of the cultured 5T33 myeloma cells is similar to the in vivo passaged tumour but, in our hands, paraprotein production, onset of paraplegia and survival time are much more consistent and reproducible when using cultured 5T33 cells than when using BM cells from tumourbearing animals. This is probably due both to selection pressure of in vitro culture conditions on tumour subpopulations and to the variable number of tumour cells present in the BM of end-stage animals. We have shown in this study that the kinetics of 5T33 myeloma progression and tissue distribution in vivo are directly related to tumour cell dose. In addition, as few as 500 myeloma cells were found to be sufficient to induce malignancy which has important implications for clinical procedures utilising purged autologous bone marrow transplantation for the treatment of multiple myeloma. Based on this experimental evidence, purging procedures would have to achieve a bone marrow preparation containing less than 500 tumour cells to minimise recrudescence.
The extensive liver, spleen and bone marrow involvement observed during 5T33 tumour progression occurred whether using cultured 5T33 myeloma cells or in vivo passaged bone marrow cells as the inoculum. Spleen and bone marrow involvement has also been found for the 5T2 myeloma, but no liver involvement was described for this subline (Radl et al., 1988) . In our animals, liver involvement with 5T2 and 5T7 myeloma was not observed (unpublished data). The 5T33 myeloma did however involve the liver and may represent a different tumour type of myeloma. In the human disease, the type of myeloma has important implications in terms of prognosis and responsiveness to therapy (Croese, 1987a; Bartl et al., 1982) .
With the establishment of the 5T33 myeloma model as a cultured cell line, animals are no longer required for in vivo tumour maintenance thereby reducing animal use to direct experimental procedures. In addition, the development of this cultured cell line now allows a more detailed evaluation of myeloma cell susceptibility to a wide range of chemotherapeutic drugs and biological response modifiers. In vitro sensitivity studies using both human and animal tumour cell lines have been shown to be predictive of patient responsiveness, particularly in determining tumour resistance (van Hoff, 1990) . The predictive value of in vitro sensitivity testing allows a systematic assessment of therapeutic options thereby providing a rational basis for treatment selection without placing patients at risk. Preliminary studies are underway using the cultured 5T33 myeloma cell line to evaluate the in vitro and in vivo susceptibility of this cell type to various forms of therapy including melphalan chemotherapy, internal radionuclide therapy using '53Samarium-ethylene-diaminetetramethylene phosphonate, and immunotherapy using cytokines such as the interferons alpha, beta and gamma, tumour necrosis factor and the interleukins 1, 2 4, & 6.
The 5T33 cell line appears to be the first of this series of seven murine myelomas which does not require IL-6 for short-or long-term growth in culture (Dr J. Radl and Dr R. Mundy, personal communication). Other differences in growth factor production and/or requirements of myeloma cells are currently being evaluated using the cultured 5T33 cell line and early passages of 5T2 and 5T7 myeloma cells. Such differences may correlate with the degree of differentiation and pattern of growth in the bone marrow and therefore could be of direct clinical relevance. Collaborative studies have also been initiated to examine alterations in oncogene expression of the murine myeloma cell lines compared with that of their human counterparts.
Transplantable murine myeloma lines have allowed detailed study of the biology and histopathology of this type of malignancy. It is anticipated that our establishment of a well-characterised cultured cell line of 5T33 murine myeloma will provide specific information on growth factor requirements, therapeutic susceptibility and genetic alterations inherent in myeloma development with the potential for direct application to human multiple myeloma.
